Sepsis Set Back: AstraZeneca CytoFab Development Will Be Delayed Two Years

The company will conduct a 21-month Phase II study prior to initiating a Phase III trial.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet